《中国急性缺血性卒中诊治指南2023》解读

doi:10.3969/j.issn.1673-5765.2024.08.013

摘要/Abstract

摘要： 2024年6月，《中华神经科杂志》发布了更新版的《中国急性缺血性卒中诊治指南2023》。该指南基于最新的循证医学证据，提供了急性缺血性卒中（acute ischemic stroke，AIS）诊治的最新推荐意见，涵盖急性期静脉溶栓、机械取栓、二级预防抗血小板治疗等多个方面。本文深入剖析这些关键推荐，结合AIS领域的最新研究成果，对相关文献进行深入解读。本文旨在清晰呈现AIS的最新诊治规范，为临床医师提供实用的指导，以更好地服务AIS患者，改善其治疗效果。

关键词: 缺血性卒中; 诊断; 治疗; 指南

Abstract: In June 2024, the Chinese Journal of Neurology published an updated version of the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023. This guideline, grounded in the latest evidence-based medicine, provides the most recent recommendations for the diagnosis and treatment of acute ischemic stroke (AIS), covering multiple aspects, such as intravenous thrombolysis in the acute phase of AIS, mechanical thrombectomy and antiplatelet therapy in secondary prevention. This article intended to delve into these key recommendations, integrating the latest research findings in the field of AIS, and to provide a thorough interpretation of related literature. The purpose of this article is to present the most up-to-date standards of the diagnosis and treatment of AIS, offering practical guidance for clinicians, thereby enhancing the quality of service for AIS patients and improving treatment outcomes.

Key words: Ischemic stroke; Diagnosis; Treatment; Guideline

中图分类号:

李光硕, 赵性泉. 《中国急性缺血性卒中诊治指南2023》解读[J]. 中国卒中杂志, 2024, 19(8): 956-961.

LI Guangshuo, ZHAO Xingquan. Interpretation of the Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023[J]. Chinese Journal of Stroke, 2024, 19(8): 956-961.

参考文献

[1] HE J，ZHANG Y H，XU T，et al. Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke：the CATIS randomized clinical trial[J]. JAMA，2014，311（5）：479-489.

[2] LIU L P，XIE X W，PAN Y S，et al. Early versus delayed antihypertensive treatment in patients with acute ischaemic stroke：multicentre，open label，randomised，controlled trial[J/OL]. BMJ，2023，383：e076448
[2023-11-01]. https://doi.org/10.1136/bmj-2023-076448.

[3] MAZIGHI M，RICHARD S，LAPERGUE B，et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke（BP-TARGET）：a multicentre，open-label，randomised controlled trial[J]. Lancet Neurol，2021，20（4）：265-274.

[4] YANG P F，SONG L L，ZHANG Y W，et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke（ENCHANTED2/MT）：a multicentre，open-label，blinded-endpoint，randomised controlled trial[J]. Lancet，2022，400（10363）：1585-1596.

[5] NAM H S，KIM Y D，HEO J，et al. Intensive vs. conventional blood pressure lowering after endovascular thrombectomy in acute ischemic stroke：the OPTIMAL-BP randomized clinical trial[J]. JAMA，2023，330（9）：832-842.

[6] MISTRY E A，HART K W，DAVIS L T，et al. Blood pressure management after endovascular therapy for acute ischemic stroke：the BEST-Ⅱ randomized clinical trial[J]. JAMA，2023，330（9）：821-831.

[7] TORBEY M T，PAULS Q，GENTILE N，et al. Intensive versus standard treatment of hyperglycemia in acute ischemic stroke patient：a randomized clinical trial subgroups analysis[J]. Stroke，2022，53（5）：1510-1515.

[8] HACKE W，KASTE M，BLUHMKI E，et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med，2008，359（13）：1317-1329.

[9] THOMALLA G，SIMONSEN C Z，BOUTITIE F，et al. MRI-guided thrombolysis for stroke with unknown time of onset[J]. N Engl J Med，2018，379（7）：611-622.

[10] MA H，CAMPBELL B C V，PARSONS M W，et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke[J]. N Engl J Med，2019，380（19）：1795-1803.

[11] MENON B K，BUCK B H，SINGH N，et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada（AcT）：a pragmatic，multicentre，open-label，registry-linked，randomised，controlled，non-inferiority trial[J]. Lancet，2022，400（10347）：161-169.

[12] WANG Y J，LI S Y，PAN Y S，et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events（TRACE-2）：a phase 3，multicentre，open-label，randomised controlled，non-inferiority trial[J]. Lancet，2023，401（10377）：645-654.

[13] BIVARD A，ZHAO H，CHURILOV L，et al. Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne mobile stroke unit（TASTE-A）：a phase 2，randomised，open-label trial[J]. Lancet Neurol，2022，21（6）：520-527.

[14] CAMPBELL B C V，MITCHELL P J，CHURILOV L，et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke[J]. N Engl J Med，2018，378（17）：1573-1582.

[15] GOYAL M，MENON B K，VAN ZWAM W H，et al. Endovascular thrombectomy after large-vessel ischaemic stroke：a meta-analysis of individual patient data from five randomised trials[J]. Lancet，2016，387（10029）：1723-1731.

[16] NOGUEIRA R G，JADHAV A P，HAUSSEN D C，et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct[J]. N Engl J Med，2018，378（1）：11-21.

[17] ALBERS G W，MARKS M P，KEMP S，et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging[J]. N Engl J Med，2018，378（8）：708-718.

[18] TAO C R，NOGUEIRA R G，ZHU Y Y，et al. Trial of endovascular treatment of acute basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1361-1372.

[19] JOVIN T G，LI C H，WU L F，et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion[J]. N Engl J Med，2022，387（15）：1373-1384.

[20] YOSHIMURA S，SAKAI N，YAMAGAMI H，et al. Endovascular therapy for acute stroke with a large ischemic region[J]. N Engl J Med，2022，386（14）：1303-1313.

[21] HUO X C，MA G T，TONG X，et al. Trial of endovascular therapy for acute ischemic stroke with large infarct[J]. N Engl J Med，2023，388（14）：1272-1283.

[22] ZI W J，QIU Z M，LI F L，et al. Effect of endovascular treatment alone vs. intravenous alteplase plus endovascular treatment on functional independence in patients with acute ischemic stroke：the DEVT randomized clinical trial[J]. JAMA，2021，325（3）：234-243.

[23] YANG P F，ZHANG Y W，ZHANG L，et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke[J]. N Engl J Med，2020，382（21）：1981-1993.

[24] SUZUKI K，MATSUMARU Y，TAKEUCHI M，et al. Effect of mechanical thrombectomy without vs. with intravenous thrombolysis on functional outcome among patients with acute ischemic stroke：the SKIP randomized clinical trial[J]. JAMA，2021，325（3）：244-253.

[25] LECOUFFE N E，KAPPELHOF M，TREURNIET K M，et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke[J]. N Engl J Med，2021，385（20）：1833-1844.

[26] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.

[27] WANG Y J，MENG X，WANG A X，et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med，2021，385（27）：2520-2530.

[28] ZI W J，SONG J X，KONG W L，et al. Tirofiban for stroke without large or medium-sized vessel occlusion[J]. N Engl J Med，2023，388（22）：2025-2036.

[29] CHEN H S，CUI Y，ZHOU Z H，et al. Dual antiplatelet therapy vs. alteplase for patients with minor nondisabling acute ischemic stroke：the ARAMIS randomized clinical trial[J]. JAMA，2023，329（24）：2135-2144.

[30] OLDGREN J，ÅSBERG S，HIJAZI Z，et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation（TIMING）：a registry-based randomized controlled noninferiority study[J]. Circulation，2022，146（14）：1056-1066.

[31] FISCHER U，KOGA M，STRBIAN D，et al. Early versus later anticoagulation for stroke with atrial fibrillation[J]. N Engl J Med，2023，388（26）：2411-2421.

[32] ENOMOTO M，ENDO A，YATSUSHIGE H，et al. Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy[J]. Stroke，2019，50（3）：652-658.

[33] KOBAYASHI S，FUKUMA S，IKENOUE T，et al. Effect of edaravone on neurological symptoms in real-world patients with acute ischemic stroke[J]. Stroke，2019，50（7）：1805-1811.

[34] XU J，WANG Y L，WANG A X，et al. Safety and efficacy of edaravone dexborneol versus edaravone for patients with acute ischaemic stroke：a phase Ⅱ，multicentre，randomised，double-blind，multiple-dose，active-controlled clinical trial[J]. Stroke Vasc Neurol，2019，4（3）：109-114.

[35] XU J，WANG A X，MENG X，et al. Edaravone dexborneol versus edaravone alone for the treatment of acute ischemic stroke：a phase Ⅲ，randomized，double-blind，comparative trial[J]. Stroke，2021，52（3）：772-780.

[36] DONG Y，ZHANG J Y，WANG Y X，et al. Effect of ginkgolide in ischemic stroke patients with large artery atherosclerosis：results from a randomized trial[J]. CNS Neurosci Ther，2021，27（12）：1561-1569.

[37] ZHANG X T，ZHONG W S，MA X D，et al. Ginkgolide with intravenous alteplase thrombolysis in acute ischemic stroke improving neurological function：a multicenter，cluster-randomized trial（giant）[J/OL]. Front Pharmacol，2021，12：792136[2023-11-01].
https://doi.org/10.3389/fphar.2021.792136.

[38] ZHANG Q，WANG A X，XU Q，et al. Efficacy and safety of ginkgo diterpene lactone meglumine in acute ischemic stroke：a randomized clinical trial[J/OL]. JAMA Netw Open，2023，6：e2328828[2023-11-01]. https://doi.org/10.1001/jamanetworkopen.2023.28828.